Press release content from Business Wire. The AP news staff was not involved in its creation.
BigHat Biosciences Raises $19 Million in Series A Funding to Advance Antibody Design and Development for Safer, More Effective Treatments
February 10, 2021 GMT
BigHat co-founders Mark DePristo and Peyton Greenside (Photo: Business Wire)
SAN CARLOS, Calif. (BUSINESS WIRE) Feb 10, 2021
BigHat Biosciences, a novel protein therapeutics company and developer of an AI-guided antibody design platform, today announced it has raised $19 million in an oversubscribed Series A funding round, led by Andreessen Horowitz, with participation from prior investors 8VC, AME Cloud Ventures and Innovation Endeavors. As part of the investment, Andreessen Horowitz General Partner, Vineeta Agarwala, MD, PhD joins BigHat’s Board of Directors.